Maurizio Fava, MD, discusses treatment-resistant depression, the placebo response, ketamine research, mentorship, and where AI fits into psychiatry's future.
Maurizio Fava, MD
Advertisement
Dr Fava is associate dean for clinical and translational research at Harvard Medical School in Boston, Massachusetts. He is psychiatrist-in-chief in the Department of Psychiatry at Massachusetts General Hospital and vice chair of the Executive Committee on Research at the Massachusetts General Hospital in Boston. He is also executive director of the Clinical Trials Network & Institute, and the Slater Family Professor of Psychiatry at Harvard Medical School.
Articles by Maurizio Fava, MD
Learn insights from an early investigator of treatment-resistant depression and expert in the field.
Recent trials reveal LSD's potential to significantly reduce anxiety symptoms in GAD, offering a promising alternative to traditional treatments.
The original STAR*D authors refute claims of a violated protocol.
Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5